Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla" today announced a significant expansion of ...

SEBI-registered analyst Dhruv Tuli of Ascend Wealth noted Cipla’s strong technical breakout backed by momentum and volume, ...

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

In conclusion, several Nifty 50 stocks, including Cipla, Sun Pharma and Infosys, experienced declines in Wednesday's trading ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

Mumbai-based pharmaceutical major Cipla has reported its financial results for the April-June period, with a better-than-expected net profit of Rs 1,298 crore and margin steady at 25.6 per cent. Cipla ...

Cipla , India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs.

Jagadeesan Joins Team India, Takes Part In Training Session Ahead Of Crucial 5th Test At The Oval; Video Vasai-Virar Illegal ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The company expects continued growth from respiratory product launches and emerging ...

The sale of a stake in Cipla Ltd. is in jeopardy as potential buyers have balked at the 1.09 trillion rupee ($13.1 billion) valuation members of the founding family are targeting for the Indian ...

India's Cipla (CIPL.NS) said on Saturday that its manufacturing of the COVID-19 remdesivir drug was beginning to catch up with demand after the company sought to boost production amid a massive ...

Cipla--one of India's largest generic-drug manufacturers--said it is cutting prices for three cancer medicines it sells in India by up to 63%.